A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Isatuximab (Primary) ; Dexamethasone; Dexamethasone; Pomalidomide
- Indications Multiple myeloma; Plasmacytoma
- Focus Registrational; Therapeutic Use
- Acronyms ICARIA; ICARIA-MM
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 14 Nov 2023 Status changed from active, no longer recruiting to completed.
- 08 Oct 2023 This trial has been completed in Sweden.
- 04 Oct 2023 This trial has been completed in Spain.